Cytotoxic effects induced by interferon-ω gene lipofection through ROS generation and mitochondrial membrane potential disruption in feline mammary carcinoma cells

Cytokine

Volumn 84, Issue , 2016, Pages 47-55

  Villaverde, Marcela Solange ^a   Targovnik, Alexandra Marisa ^a   Miranda, María Victoria ^a   Finocchiaro, Liliana María Elena ^a   Glikin, Gerardo Claudio ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Feline interferon omega; Feline mammary carcinoma; Plasmid lipofection; ROS

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALCIUM; CYTOKERATIN 18; CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INTERFERON; KI 67 ANTIGEN; LIPOSOME; OMEGA INTERFERON; PROGESTERONE RECEPTOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; INTERFERON OMEGA 1;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CALCIUM TRANSPORT; CAT; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CYTOTOXICITY; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VETERINARY MEDICINE; ANIMAL; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CALCIUM; CATS; CELL LINE, TUMOR; FEMALE; INTERFERON TYPE I; MAMMARY NEOPLASMS, ANIMAL; MEMBRANE POTENTIAL, MITOCHONDRIAL; REACTIVE OXYGEN SPECIES;

EID: 84969776500     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.05.018     Document Type: Article

References (34)

1. Baba A.I., Câtoi C. Comparative Oncology 2007, The Publishing House of the Romanian Academy, Bucharest.
2. Babiychuk E.B., Monastyrskaya K., Potez S., Draeger A. Blebbing confers resistance against cell lysis. Cell Death Differ. 2011, 18:80-89.
3. Belardelli F., Ferrantini M., Proietti E., Kirkwood J.M. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002, 13:119-134.
4. Burrai G.P., Mohammed S.I., Miller M.A., Marras V., Pirino S., Addis M.F., Uzzau S., Antuofermo E. Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions. BMC Cancer 2010, 10:156.
5. Chen P.F., Fu G.F., Zhang H.Y., Xu G.X., Hou Y.Y. Liposomal plasmid DNA encoding human thymosin alpha and interferon omega potently inhibits liver tumor growth in ICR mice. J. Gastroenterol. Hepatol. 2006, 21:1538-1543.
6. Cheng J.C., Klausen C., Leung P.C. Hydrogen peroxide mediates EGF-induced down-regulation of E-Cadherin expression via p38 MAPK and snail in human ovarian cancer cells. Mol. Endocrinol. 2010, 24:1569-1580.
7. De Maria R., Olivero M., Iussich S., Nakaichi M., Murata T., Biolatti B., Di Renzo M.F. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res. 2005, 65:907-912.
8. Finocchiaro L.M., Fondello C., Gil-Cardeza M.L., Rossi Ú.A., Villaverde M.S., Riveros M.D., Glikin G.C. Cytokine-enhanced vaccine and interferon-β plus suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma. Hum. Gene Ther. 2015, 26:367-376.
9. Friedrich J., Seidel C., Ebner R., Kunz-Schughart L.A. Spheroid-based drug screen: considerations and practical approach. Nat. Protoc. 2009, 4:309-324.
10. Gerdes J., Lemke H., Baisch H., Wacker H.H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 1984, 133:1710-1715.
11. Glikin G.C., Finocchiaro L.M. Clinical trials of immunogene therapy for spontaneous tumors in companion animals. Sci. World J. 2014, 2014:718520.
12. Hsieh J.L., Lu C.S., Huang C.L., Shieh G.S., Su B.H., Su Y.C., Lee C.H., Chang M.Y., Wu C.L., Shiau A.L. Acquisition of an enhanced aggressive phenotype in human lung cancer cells selected by suboptimal doses of cisplatin following cell deattachment and reattachment. Cancer Lett. 2012, 321:36-44.
13. Hughes K., Dobson J.M. Prognostic histopathological and molecular markers in feline mammary neoplasia. Vet. J. 2012, 194:19-26.
14. Jonasch E., Haluska F.G. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001, 6:34-55.
15. Lana S.E., Rutteman G.R., Withrow S.J. Tumors of the mammary gland. Withrow & MacEwen's Small Animal Clinical Oncology 2007, 619-636. Saunders, St. Louis. S.J. Withrow, D.M. Vail (Eds.).
16. Manesh J.Y., Shafiee R., Pedram B., Malayeri H.Z., Mohajer S., Ahmadi S., Ahmadi S., Javanbakht J., Mokarizadeh A., Khadivar F. Improving the diagnosis, treatment, and biology patterns of feline mammary intraepithelial lesions: a potential model for human breast masses with evidence from epidemiologic and cytohistopathologic studies. Tumour Biol. 2014, 35:12109-12117.
17. Martín de las Mulas J., Van Niel M., Millán Y., Ordás J., Blankenstein M.A., Van Mil F., Misdorp W. Progesterone receptors in normal, dysplastic and tumourous feline mammary glands. Comparison with oestrogen receptors status. Res. Vet. Sci. 2002, 72:153-161.
18. Martin P.M., Cotard M., Mialot J.P., André F., Raynaud J.P. Animal models for hormone-dependent human breast cancer. Relationship between steroid receptor profiles in canine and feline mammary tumors and survival rate. Cancer Chemother. Pharmacol. 1984, 12:13-17.
19. Millanta F., Calandrella M., Citi S., Della Santa D., Poli P. Overexpression of HER-2 in feline invasive mammary carcinomas: an immunohistochemical survey and evaluation of its prognostic potential. Vet. Pathol. 2005, 42:30-34.
20. Millanta F., Calandrella M., Vannozzi I., Poli A. Steroid hormone receptors in normal, dysplastic and neoplastic feline mammary tissues and their prognostic significance. Vet. Rec. 2006, 158:821-824.
21. Ocaña O.H., Córcoles R., Fabra A., Moreno-Bueno G., Acloque H., Vega S., Barrallo-Gimeno A., Cano A., Nieto M.A. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012, 22:709-724.
22. Penzo C., Ross M., Muirhead R., Else R., Argyle D.J. Effect of recombinant feline interferon-omega alone and in combination with chemotherapeutic agents on putative tumour-initiating cells and daughter cells derived from canine and feline mammary tumours. Vet. Comp. Oncol. 2009, 7:222-229.
23. Pisco A.O., Huang S. Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'what does not kill me strengthens me'. Br. J. Cancer 2015, 112:1725-1732.
24. Potapova T.A., Zhu J., Li R. Aneuploidy and chromosomal instability: a vicious cycle driving cellular evolution and cancer genome chaos. Cancer Metastasis Rev. 2013, 32:377-389.
25. Rossi Ú.A., Gil-Cardeza M.L., Villaverde M.S., Finocchiaro L.M., Glikin G.C. Interferon-β gene transfer induces a strong cytotoxic bystander effect on melanoma cells. Biomed. Pharmacother. 2015, 72:44-51.
26. Santos S., Bastos E., Baptista C.S., Sá D., Caloustian C., Guedes-Pinto H., Gärtner F., Gut I.G., Chaves R. Sequence variants and haplotype analysis of cat ERBB2 gene: a survey on spontaneous cat mammary neoplastic and nonneoplastic lesions. Int. J. Mol. Sci. 2012, 13:2783-2800.
27. Targovnik A.M., Villaverde M.S., Arregui M.B., Fogar M., Taboga O., Glikin G.C., Finocchiaro L.M.E., Cascone O., Miranda M.V. Expression and purification of recombinant feline interferon in the baculovirus-insect larvae system. Process Biochem. 2014, 49:917-926.
28. Tateyama S., Priosoeryanto B.P., Yamaguchi R., Uchida K., Ogiwara K., Suchiya A.T. In vitro growth inhibition activities of recombinant feline interferon on all lines derived from canine tumours. Res. Vet. Sci. 1995, 59:275-277.
29. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
30. Villaverde M.S., Gil-Cardeza M.L., Glikin G.C., Finocchiaro L.M. Interferon-β lipofection II. Mechanisms involved in cell death and bystander effect induced by cationic lipid-mediated interferon-β gene transfer to human tumor cells. Cancer Gene Ther. 2012, 19:420-430.
31. Wiese D.A., Thaiwong T., Yuzbasiyan-Gurkan V., Kiupel M. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype. BMC Cancer 2013, 13:403.
32. Zatoński T., Krecicki T., Duś D., Zalesska-Krecicka M., Jeleń M., Kaczmarz M. S+G2M phase fraction and index of DNA in the aneuploid laryngeal cancer. Otolaryngol. Pol. 2004, 58:321-326.
33. Zheng G., Lyu J., Huang J., Xiang D., Xie M., Zeng Q. Experimental treatments for mitochondrial dysfunction in sepsis: a narrative review. J. Res. Med. Sci. 2015, 20:185-195.
34. Zitvogel L., Galluzzi L., Kepp O., Smyth M.J., Kroemer G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 2015, 15:405-414.